India's drug regulator on Tuesday allowed vaccine maker Serum Institute to enrol children aged 7-11 years for its COVID-19 vaccine trial as the country prepares to protect kids from the coronavirus.
It has already administered more than 870 million doses to adults among its population of nearly 1.4 billion.
"After detailed deliberation, the committee recommended for allowing enrolment of subjects of 7 to 11 years of age group as per the protocol," a subject expert panel of the Central Drugs Standard Control Organisation said.
Serum Institute is already conducting a trial of its COVID-19 vaccine, a domestically produced version of US drugmaker Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.
So far, only drugmaker Zydus Cadila's DNA COVID-19 vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above.
Trump-Putin summit cancelled, FT reports
Houthis say 43 detained UN staff to face trial over Israeli attack
Hurricane Melissa leaves 49 dead in Caribbean, churns north
King Charles strips brother Andrew of titles and his mansion
Vietnam flood death toll rises to 13, with 11 others missing
